Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL987142 | 0.84 | TSHR (0.43) | TSHRACHECYP1A2CYP2A6MEN1 | |
| SCHEMBL29237033 | 0.82 | ACHE (0.41) | TSHRACHECYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL1960743 | 0.79 | TSHR (0.43) | TSHRACHECYP1A2CYP2A6MEN1 | |
| SCHEMBL29431181 | 0.79 | TSHR (0.43) | TSHRACHECYP1A2CYP2A6MEN1 | |
| SCHEMBL2453376 | 0.79 | TSHR (0.43) | TSHRACHECYP1A2CYP2A6MEN1 | |
| SCHEMBL1315179 | 0.79 | TRPA1 (0.35) | TRPA1ATMTSHRACHECYP1A2 | |
| SCHEMBL1316141 | 0.79 | TRPA1 (0.35) | TRPA1ATMTSHRACHECYP1A2 | |
| SCHEMBL12814759 | 0.79 | — | — | |
| SCHEMBL12814736 | 0.79 | — | — | |
| SCHEMBL4957410 | 0.78 | TRPA1 (0.34) | TRPA1ATMTSHRACHECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290491-A | Copper nanocluster and preparation method thereof | 清华大学 | 2024-07-05 | — | — | CN | disclosed |
| CN-116727659-A | Chiral copper nanocluster and preparation method thereof | 清华大学 | 2023-09-12 | — | — | CN | disclosed |
| EP-2275427-B1 | Ruthenium-diamine complex and methods for producing optically active compounds | TAKASAGO PERFUMERY CO LTD (JP) | 2013-09-11 | — | — | EP | disclosed |
| US-8404879-B2 | Ruthenium-diamine complex and methods for producing optically active compounds | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-03-26 | — | — | US | disclosed |
| EP-2258707-B1 | Ruthenium silyl-arene complexes, and method for production thereof | TAKASAGO PERFUMERY CO LTD (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-7880025-B2 | complexing trimethyl(4-methyl-1,4-cyclohexadienyl)silane with ruthenium chloride to produce RuCl2 [trimethyl (4-methyl-1,4-cyclohexadienyl) silane] | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-2275427-A1 | Ruthenium-diamine complex and methods for producing optically active compounds | Takasago International Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-20110009646-A1 | RUTHENIUM-DIAMINE COMPLEX AND METHODS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2258707-A1 | Ruthenium silyl-arene complexes, and method for production thereof | Takasago International Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-20100298588-A1 | RUTHENIUM SILYL-ARENE COMPLEX , AND METHOD FOR PRODUCTION THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298588-A1 | RUTHENIUM SILYL-ARENE COMPLEX , AND METHOD FOR PRODUCTION THEREOF | SPR, LSS, SRI | TRPA1 1563/4885ATM 3172/4885TSHR 4573/4885 |
| US-20110009646-A1 | RUTHENIUM-DIAMINE COMPLEX AND METHODS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | ADH5, AOC1, ADH1A | TRPA1 1431/4885ATM 2758/4885TSHR 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.